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cute Coronary Syndromes
on’t Bypass the Clopidogrel*
olin M. Barker, MD,†
. Vernon Anderson, MD‡
a Jolla, California; and Houston, Texas
he thienopyridine agent clopidogrel, added to aspirin and
ntithrombin therapies, benefits patients with non–ST-
egment elevation acute coronary syndromes (ACS). The
fficacy of clopidogrel compared with placebo in these
atients was firmly established first in the CURE (Clopi-
ogrel in Unstable Angina to Prevent Recurrent Events)
rial, in which there was an absolute reduction in the
rimary end point (cardiovascular death, myocardial infarc-
ion, and stroke) of 2.1% (1). The relative risk of clopidogrel
ompared with placebo was 0.80. This risk reduction was
qually present in patients treated either medically or, very
mportantly, with revascularization. Clopidogrel reduced
he risk overall of ischemic vascular events, with effects
oticeable within 24 h of initiation of treatment and
ontinuing for up to 12 months (2). Thus, the current
merican College of Cardiology/American Heart Associa-
ion (ACC/AHA) guidelines for managing patients with
CS include a Class I recommendation (Level of Evidence:
) for early dual antiplatelet therapy with aspirin and either
lopidogrel or, alternatively, a glycoprotein IIb/IIIa inhibi-
or (3). The emphasis here is on the word “early.”
See page 1965
Effective platelet inhibition comes with a potential cost of
ncreased bleeding. In the CURE trial, dual antiplatelet
herapy compared with aspirin alone was associated with
ignificant increases in major bleeding (3.7% vs. 2.7%) and
inor bleeding (5.1% vs. 2.4%), but not in life-threatening
leeding events (2.2% vs. 1.8%). Bleeding was more com-
on in the patients requiring coronary artery bypass surgery
CABG) for their coronary disease, but only when clopi-
ogrel was discontinued 5 days before surgery (1). Other
eports have confirmed this. In the CRUSADE (Can Rapid
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Scripps Clinic, La Jolla, California; and the ‡University of Texas Health
cience Center, Houston, Texas. Dr. Anderson has received honoraria for speakingi
ngagements from Bristol-Myers Squibb, Sanofi-Aventis, Daiichi Sankyo, PDL
iopharma, and The Medicines Company.isk Stratification of Unstable Angina Patients Suppress
dverse Outcomes with Early Implementation of the
CC/AHA Guidelines) registry, patients who underwent
ABG within 5 days of discontinuing clopidogrel had a
ignificant increase in blood transfusions (65% vs. 57%) (4).
n contrast, if CABG was delayed 5 days after stopping
lopidogrel, bleeding was similar to that in those patients
ho had not received it. A multicenter, retrospective cohort
nalysis of 596 randomly selected ACS patients requiring
ABG showed that discontinuing clopidogrel within 5 days
efore surgery increased risks for reoperation, major bleed-
ng, and longer length of stay (5). Thus, the ACC/AHA
uidelines also contain the recommendation to withhold
lopidogrel for 5 to 7 days before CABG (3). Yet somehow,
espite the guideline recommendations and the data behind
hem, some centers do not routinely administer early,
pfront clopidogrel to all ACS patients. Ostensibly the
easoning for this is the increased bleeding risk that may
rise if the ACS patients were to need CABG. This concern
revails, although only 10% to 15% of ACS patients will
equire CABG during their hospitalization (1,4,6).
In this issue of the Journal, Ebrahimi et al. (7) present
ata from the ACUITY (Acute Catheterization and Urgent
ntervention Triage Strategy) trial on this topic. In this
arge, prospective, randomized study of ACS patients un-
ergoing early invasive management, the timing of clopi-
ogrel initiation was left to investigator discretion, but was
arefully recorded in the case report forms. A 5-day delay
efore CABG was recommended for patients who received
lopidogrel. In this trial, 1,539 (11.1%) of the patients
nderwent CABG before discharge, and 50.9% had re-
eived clopidogrel before surgery. The patients exposed to
lopidogrel had a longer median duration of hospitalization,
ut lower rates of composite ischemic events (death, myo-
ardial infarction, or unplanned revascularization) at 30
ays, primarily because of fewer myocardial infarctions in
he clopidogrel-treated patients. By multivariate analysis,
lopidogrel exposure before CABG was an independent
redictor of freedom from composite ischemia at 30 days
odds ratio: 0.67, 95% confidence interval: 0.48 to 0.92, p
.001). Furthermore, there was no association between
lopidogrel exposure and both non-CABG and post-
ABG major bleeding. Regarding the timing of clopidogrel
xposure, those who received the drug and underwent
ABG within 5 days had comparable rates of ischemia at
0 days and 1 year, with no difference in bleeding before or
fter surgery, when compared with those who never received
lopidogrel. Interestingly, those exposed to clopidogrel who
ent for surgery5 days after the last dose had significantly
ower rates of 30-day (8.8% vs. 17.3%, p  0.001) and
-year (14.9% vs. 21.4%, p  0.02) composite ischemia and
ess transfusions compared with those not exposed. Finally,
hen tabulated as net adverse clinical events to account for
oth types of unwanted outcomes, including composite
schemia or non-CABG major bleeding, the results favored
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Clopidogrel in ACS May 26, 2009:1973–4arly clopidogrel administration followed by 5-day delay
or those patients needing CABG; this group had the lowest
et adverse clinical events of all 3. This is precisely the
osition of the ACC/AHA guidelines (3).
This study has several limitations, but the data clearly
upport the current guidelines both in the recommendation
f early clopidogrel in all ACS patients as well as waiting
5 days in the minority of patients who will undergo
ABG. The primary limitation of this work is the lack of
obustness inherent in a retrospective analysis of an
nblinded, nonrandomized cohort. Second, the trial was
ot powered for the cohort of patients undergoing
ABG. Perhaps the greatest limitation and confounder
s the lack of data on clopidogrel use after the initial
ospitalization, because this might explain some of the
schemia benefit. The data show a strong association
etween pre-operative exposure to clopidogrel and being
ischarged on the drug, as well as between never receiv-
ng clopidogrel and not being discharged on the drug.
pecifically, 65.6% exposed were discharged on clopi-
ogrel and only 14.7% not exposed were discharged on
he drug (p  0.0001). Further studies would be neces-
ary to determine whether some of the ischemia benefit is
rom the pre-CABG exposure or the treatment after
eing discharged.
Individualized care is rapidly evolving with new discov-
ries and innovations that go beyond traditional risk factors.
n cardiology, this is especially apparent in antiplatelet
herapy. Point-of-care platelet function assays may eventu-
lly enable physicians to tailor antiplatelet therapy to the
ndividual patient. A small study on healthy volunteers
valuated platelet reactivity using the VerifyNow P2Y12
ssay (Accumetrics, San Diego, California) after a loading
ose of 600 mg clopidogrel. The data suggest that early
latelet inhibition with clopidogrel varies widely among
ndividuals, and recovery of platelet function depends less on
he number of days after the exposure and more on the
agnitude of the initial inhibition (8). If they can be
alidated in clinical use, point-of-care assays may help tailor
he management of ACS patients who go on to receive
ABG by identifying those at low risk for surgical bleeding.
dditionally, recent advances in pharmacogenomics and the
echanism of clopidogrel metabolism have generated inter-
st in applying a patient’s genetic information to antiplatelet
herapy. Carriers of certain alleles in the cytochrome P450
ystem (especially CYP 2C19*2) have lower concentrations
f the active metabolite of clopidogrel and a greater number
f ischemic events (9,10). Whether this information can be
ranslated into clinical medicine and improve patient care
emains to be seen, but it is very exciting and appears
romising.
In conclusion, even with very specific guidelines to helptandardize and improve the care of patients with ACS,
K
cuch remains in the hands of the treating physicians and
he institutions where they work. Despite the known ben-
fits of early clopidogrel administration, even on initial
ospital presentation and before coronary angiography, this
ractice is far from universal. The data presented by Ebra-
imi et al. (7) support the current ACC/AHA guideline
ecommendations, and hopefully this may sway those who
ontinue to withhold early clopidogrel despite its safety and
roven efficacy.
eprint requests and correspondence: Dr. H. Vernon Anderson,
ardiology Division, University of Texas Health Science Center,
431 Fannin, Suite 1.246, Houston, Texas 77030. E-mail: h.v.
nderson@uth.tmc.edu.
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